北京商报讯（记者 王寅浩 宋雨盈）2月6日，天士力发布2025年业绩快报，2025年实现营业收入82.36亿 元，同比下降3.08%；实现归属于上市公司股东的净利润为11.05亿元，同比增长15.68%。 根据公告，营业收入同比下降的主要原因为医药商业收入（主要为连锁药店业务）受"门诊统筹"等行业 性政策的影响同比减少14.24%。 ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

格隆汇2月6日丨天士力(600535.SH)公布2025年度业绩快报，2025年，公司正式成为华润三九旗下一 员，以创新驱动开启融合发展新篇章，顺利完成与华润三九的"百日融合"并稳步推动"首年融合"各项工 作，在业务稳定、团队稳定、客户稳定基础上，以"四个重塑"为指引，加快与华润三九的资源整合。面 对医药行业集采控费等政策因素影响，公司持续聚焦心血管及代谢、神经/精神、消化三大治疗领域， 积极推进核心业务，全面提升企业效益效率和竞争力，坚持创新驱动，实现高质量发展，向"成为中国 医药市场的领先企业"的目标稳步迈进。报告期内，公司实现营业总收入82.36亿元，同比减少3.08%； 实现归属于上市公司股东的净利润11.05亿元，同比增加15.68%。从变动幅度上看，公司营业收入同比 下降的主要原因是医药商业收入（主要为连锁药店业务）受"门诊统筹"等行业性政策的影响同比减少 14.24%。 ...

以投资者为本，重视投资者权益保护，是当前资本市场最为关注的主题之一。近期证监会发布了《关于 加强资本市场中小投资者保护的若干意见》，上交所公开倡议在沪市全面启动"提质增效重回报"专项行 动。对于上市公司来说，高质量发展是对投资者的最佳回报。2月6日晚间，天士力发布的2025年全年业 绩预告称，公司预计全年实现基本每股收益0.74元，同比增长15.63%，以高质量发展践行对投资者回报 的提高。 企业高质量发展提升投资者回报 专家指出，当前中国资本市场正从规模扩张向质量提升转型，而提升投资者回报是这一转型的核心枢 纽。资本市场长足健康发展的关键在于为投资者提供持续、合理的回报。监管层一贯重视并鼓励上市公 司通过多种方式提高投资者回报。 数据显示，"十四五"期间，上市公司通过多种形式累计向投资者派利10.6万亿元，比"十三五"时期增长 超八成，相当于同期IPO和再融资金额的2.07倍。这都源自于上市公司自身高质量的企业发展水平。 天士力历来积极响应监管层鼓励上市公司通过现金分红等方式提高投资者回报的号召。2025年上半年 度，天士力利润分配方案为每股现金红利0.21元（含税）。2024年，天士力全年共进行三次分红， ...

天士力（600535）(600535.SH)披露2025年度业绩快报，公司实现营业总收入82.36亿元，同比减少 3.08%;实现归属于上市公司股东的净利润11.05亿元，同比增加15.68%。 据悉，公司营业收入同比下降的主要原因是医药商业收入(主要为连锁药店业务)受"门诊统筹"等行业性 政策的影响同比减少14.24%。 ...

天士力(600535.SH)披露2025年度业绩快报，公司实现营业总收入82.36亿元，同比减少3.08%;实现归属 于上市公司股东的净利润11.05亿元，同比增加15.68%。 据悉，公司营业收入同比下降的主要原因是医药商业收入(主要为连锁药店业务)受"门诊统筹"等行业性 政策的影响同比减少14.24%。 ...

股票代码：600535 股票简称：天士力 公告编号：临 2026-002 号 由于 Arbor 公司已被 Azurity Pharmaceuticals, Inc.（简称"Azurity 公司"） 收购，目前正在进行业务调整，经双方友好协商，决定终止合作并共同签署《终 止协议》，天士力对 Arbor 公司 T89 相关适应症在美国的独家销售权等权益据此 终止。根据《许可协议》，公司最终收到相关款项 750 万美元。 上述与 Arbor 公司签署《终止协议》事项已经公司于 2026 年 2 月 6 日召开 的第九届董事会第 17 次会议审议，以 15 票赞成，0 票反对，0 票弃权的表决结 果审议通过。本次会议为通讯方式召开，会议通知于 2026 年 2 月 2 日以书面方 式发出，会议应到董事 15 人，实到董事 15 人，会议符合《公司法》和《公司章 程》的有关规定，会议合法、有效。本议案无需提交公司股东会审议。 二、协议对方基本情况 Arbor 公司成立于 2006 年，是一家总部位于美国的制药公司，该公司于 2021 年 8 月被 Azurity 公司收购，现为 Azurity 公司的全资子公司。Azu ...

股票代码：600535 股票简称：天士力 公告编号：临 2026-001 号 天士力医药集团股份有限公司 注：以上财务数据及指标以公司合并报表数据填列，最终结果以公司2025年度报告为准。 二、经营业绩和财务状况情况说明 1 2025 年度业绩快报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特别提示：本公告所载 2025 年度的财务数据为天士力医药集团股份有限公 司（以下简称"公司"）初步核算数据，未经会计师事务所审计，与 2025 年度 报告中披露的最终数据可能存在差异，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 年 2025 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | 营业总收入 | 823,647.74 | 849,814.19 | -3.08% | | 营业利润 | 135,041.38 | 107,592.25 | 25.51% | | 利润总额 | 134,066.12 | 106,868.98 | 25.45% | ...

南财智讯2月6日电，天士力发布2025年度业绩快报，报告期内公司实现营业收入82.36亿元，同比下降 3.08%；归属于上市公司股东的净利润11.05亿元，同比增长15.68%；基本每股收益0.74元，同比增长 15.63%。 ...

天士力公告称，公司与美国Arbor公司于2018年签署《许可协议》，授予其复方丹参滴丸相关适应症在 美国的独家销售等权益。因Arbor公司被Azurity公司收购并进行业务调整，双方协商签署《终止协 议》，天士力收回相关权益。公司最终收到相关款项750万美元，本次终止合作不会对公司项目推进、 生产经营及财务状况产生重大影响。 ...